Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan combinations in HER2-positive metastatic breast cancer
NCT04538742Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 15
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in breast cancer, sponsored by AstraZeneca. Started Dec 2020; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04538742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538742.